Candel Therapeutics, Inc. CADL Non Cash Interest Expense
Non Cash Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cadl:NonCashInterestExpense.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s non cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s non cash interest expense?
- Candel Therapeutics, Inc. (CADL) reported non cash interest expense of $39K in Q1 2026.
- How has Candel Therapeutics, Inc.'s non cash interest expense changed year-over-year?
- Candel Therapeutics, Inc.'s non cash interest expense increased by 14.7% year-over-year, from $34K to $39K.
- What is the long-term trend for Candel Therapeutics, Inc.'s non cash interest expense?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s non cash interest expense has grown at a 16.1% compound annual growth rate (CAGR), from $76K to $138K.
- What does non cash interest expense mean?
- This metric captures interest-related expenses that are recognized in the income statement but do not require a cash payment during the period, such as the amortization of debt issuance costs. It helps investors understand the difference between reported interest expense and actual cash interest paid.